Loading…
COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study
GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection. Participants were recruited across Ontario, Canada. Participant...
Saved in:
| Published in: | Vaccine 2024-04, Vol.42 (11), p.2733-2739 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c374t-a8f92227c9e590e8d2e8f28b1775b2fc694249533e4ab46b636db6f472f005e73 |
| container_end_page | 2739 |
| container_issue | 11 |
| container_start_page | 2733 |
| container_title | Vaccine |
| container_volume | 42 |
| creator | Morgan, Gregory Casalino, Selina Chowdhary, Sunakshi Frangione, Erika Fung, Chun Yiu Jordan Lapadula, Elisa Arnoldo, Saranya Bearss, Erin Binnie, Alexandra Borgundvaag, Bjug Briollais, Laurent Dagher, Marc Devine, Luke Friedman, Steven M Khan, Zeeshan Mighton, Chloe Nirmalanathan, Konika Richardson, David Stern, Seth Taher, Ahmed Wolday, Dawit Lerner-Ellis, Jordan Taher, Jennifer |
| description | GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection.
Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity.
Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1–2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects.
We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines. |
| doi_str_mv | 10.1016/j.vaccine.2024.03.030 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2974008883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X24003177</els_id><sourcerecordid>3037804639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-a8f92227c9e590e8d2e8f28b1775b2fc694249533e4ab46b636db6f472f005e73</originalsourceid><addsrcrecordid>eNqFkU-LFDEQxYMo7rj6EZSAFy89Vv50kj6JjOu6sDgXFW8hna5eM_SkxyS9MN_eLDN68LJQUBT86hWvHiGvGawZMPV-t7533oeIaw5crkHUgidkxYwWDW-ZeUpWwJVsJIOfF-RFzjsAaAXrnpMLYVrOlNYrst1sf9x8alhHz3I0ofNlvsMYfChH6vZzvKMHl0qdDy6WTDGmeZpwoCHS8gvp9dXXqkJzWYbjS_JsdFPGV-d-Sb5_vvq2-dLcbq9vNh9vGy-0LI0zY8c5177DtgM0A0czctMzrduej151ksuuFQKl66XqlVBDr0ap-VhNoBaX5N1J95Dm3wvmYvche5wmF3FeshWsFYYprtmjKO-0BDDGiIq-_Q_dzUuK1YgVILQBqURXqfZE-TTnnHC0hxT2Lh0tA_sQjt3Z8zftQzgWRC2oe2_O6ku_x-Hf1t80KvDhBGD93H3AZLMPGD0OIaEvdpjDIyf-AAXCn8c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3037804639</pqid></control><display><type>article</type><title>COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study</title><source>ScienceDirect Freedom Collection</source><creator>Morgan, Gregory ; Casalino, Selina ; Chowdhary, Sunakshi ; Frangione, Erika ; Fung, Chun Yiu Jordan ; Lapadula, Elisa ; Arnoldo, Saranya ; Bearss, Erin ; Binnie, Alexandra ; Borgundvaag, Bjug ; Briollais, Laurent ; Dagher, Marc ; Devine, Luke ; Friedman, Steven M ; Khan, Zeeshan ; Mighton, Chloe ; Nirmalanathan, Konika ; Richardson, David ; Stern, Seth ; Taher, Ahmed ; Wolday, Dawit ; Lerner-Ellis, Jordan ; Taher, Jennifer</creator><creatorcontrib>Morgan, Gregory ; Casalino, Selina ; Chowdhary, Sunakshi ; Frangione, Erika ; Fung, Chun Yiu Jordan ; Lapadula, Elisa ; Arnoldo, Saranya ; Bearss, Erin ; Binnie, Alexandra ; Borgundvaag, Bjug ; Briollais, Laurent ; Dagher, Marc ; Devine, Luke ; Friedman, Steven M ; Khan, Zeeshan ; Mighton, Chloe ; Nirmalanathan, Konika ; Richardson, David ; Stern, Seth ; Taher, Ahmed ; Wolday, Dawit ; Lerner-Ellis, Jordan ; Taher, Jennifer</creatorcontrib><description>GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection.
Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity.
Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1–2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects.
We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2024.03.030</identifier><identifier>PMID: 38521677</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; cohort studies ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 infection ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; Ethnicity ; Fever ; Headaches ; Hospitals ; Humans ; Immunization ; Infections ; Medical research ; mRNA ; mRNA vaccines ; Observational studies ; Ontario ; Ontario - epidemiology ; Pain ; Prospective Studies ; Questionnaires ; Reactogenicity ; Regression analysis ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Side effects ; vaccination ; Vaccine safety ; Vaccines</subject><ispartof>Vaccine, 2024-04, Vol.42 (11), p.2733-2739</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Apr 19, 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c374t-a8f92227c9e590e8d2e8f28b1775b2fc694249533e4ab46b636db6f472f005e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38521677$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morgan, Gregory</creatorcontrib><creatorcontrib>Casalino, Selina</creatorcontrib><creatorcontrib>Chowdhary, Sunakshi</creatorcontrib><creatorcontrib>Frangione, Erika</creatorcontrib><creatorcontrib>Fung, Chun Yiu Jordan</creatorcontrib><creatorcontrib>Lapadula, Elisa</creatorcontrib><creatorcontrib>Arnoldo, Saranya</creatorcontrib><creatorcontrib>Bearss, Erin</creatorcontrib><creatorcontrib>Binnie, Alexandra</creatorcontrib><creatorcontrib>Borgundvaag, Bjug</creatorcontrib><creatorcontrib>Briollais, Laurent</creatorcontrib><creatorcontrib>Dagher, Marc</creatorcontrib><creatorcontrib>Devine, Luke</creatorcontrib><creatorcontrib>Friedman, Steven M</creatorcontrib><creatorcontrib>Khan, Zeeshan</creatorcontrib><creatorcontrib>Mighton, Chloe</creatorcontrib><creatorcontrib>Nirmalanathan, Konika</creatorcontrib><creatorcontrib>Richardson, David</creatorcontrib><creatorcontrib>Stern, Seth</creatorcontrib><creatorcontrib>Taher, Ahmed</creatorcontrib><creatorcontrib>Wolday, Dawit</creatorcontrib><creatorcontrib>Lerner-Ellis, Jordan</creatorcontrib><creatorcontrib>Taher, Jennifer</creatorcontrib><title>COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection.
Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity.
Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1–2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects.
We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.</description><subject>Adult</subject><subject>cohort studies</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 infection</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>Ethnicity</subject><subject>Fever</subject><subject>Headaches</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Medical research</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Observational studies</subject><subject>Ontario</subject><subject>Ontario - epidemiology</subject><subject>Pain</subject><subject>Prospective Studies</subject><subject>Questionnaires</subject><subject>Reactogenicity</subject><subject>Regression analysis</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Side effects</subject><subject>vaccination</subject><subject>Vaccine safety</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkU-LFDEQxYMo7rj6EZSAFy89Vv50kj6JjOu6sDgXFW8hna5eM_SkxyS9MN_eLDN68LJQUBT86hWvHiGvGawZMPV-t7533oeIaw5crkHUgidkxYwWDW-ZeUpWwJVsJIOfF-RFzjsAaAXrnpMLYVrOlNYrst1sf9x8alhHz3I0ofNlvsMYfChH6vZzvKMHl0qdDy6WTDGmeZpwoCHS8gvp9dXXqkJzWYbjS_JsdFPGV-d-Sb5_vvq2-dLcbq9vNh9vGy-0LI0zY8c5177DtgM0A0czctMzrduej151ksuuFQKl66XqlVBDr0ap-VhNoBaX5N1J95Dm3wvmYvche5wmF3FeshWsFYYprtmjKO-0BDDGiIq-_Q_dzUuK1YgVILQBqURXqfZE-TTnnHC0hxT2Lh0tA_sQjt3Z8zftQzgWRC2oe2_O6ku_x-Hf1t80KvDhBGD93H3AZLMPGD0OIaEvdpjDIyf-AAXCn8c</recordid><startdate>20240419</startdate><enddate>20240419</enddate><creator>Morgan, Gregory</creator><creator>Casalino, Selina</creator><creator>Chowdhary, Sunakshi</creator><creator>Frangione, Erika</creator><creator>Fung, Chun Yiu Jordan</creator><creator>Lapadula, Elisa</creator><creator>Arnoldo, Saranya</creator><creator>Bearss, Erin</creator><creator>Binnie, Alexandra</creator><creator>Borgundvaag, Bjug</creator><creator>Briollais, Laurent</creator><creator>Dagher, Marc</creator><creator>Devine, Luke</creator><creator>Friedman, Steven M</creator><creator>Khan, Zeeshan</creator><creator>Mighton, Chloe</creator><creator>Nirmalanathan, Konika</creator><creator>Richardson, David</creator><creator>Stern, Seth</creator><creator>Taher, Ahmed</creator><creator>Wolday, Dawit</creator><creator>Lerner-Ellis, Jordan</creator><creator>Taher, Jennifer</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope></search><sort><creationdate>20240419</creationdate><title>COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study</title><author>Morgan, Gregory ; Casalino, Selina ; Chowdhary, Sunakshi ; Frangione, Erika ; Fung, Chun Yiu Jordan ; Lapadula, Elisa ; Arnoldo, Saranya ; Bearss, Erin ; Binnie, Alexandra ; Borgundvaag, Bjug ; Briollais, Laurent ; Dagher, Marc ; Devine, Luke ; Friedman, Steven M ; Khan, Zeeshan ; Mighton, Chloe ; Nirmalanathan, Konika ; Richardson, David ; Stern, Seth ; Taher, Ahmed ; Wolday, Dawit ; Lerner-Ellis, Jordan ; Taher, Jennifer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-a8f92227c9e590e8d2e8f28b1775b2fc694249533e4ab46b636db6f472f005e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>cohort studies</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 infection</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>Ethnicity</topic><topic>Fever</topic><topic>Headaches</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Medical research</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Observational studies</topic><topic>Ontario</topic><topic>Ontario - epidemiology</topic><topic>Pain</topic><topic>Prospective Studies</topic><topic>Questionnaires</topic><topic>Reactogenicity</topic><topic>Regression analysis</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Side effects</topic><topic>vaccination</topic><topic>Vaccine safety</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morgan, Gregory</creatorcontrib><creatorcontrib>Casalino, Selina</creatorcontrib><creatorcontrib>Chowdhary, Sunakshi</creatorcontrib><creatorcontrib>Frangione, Erika</creatorcontrib><creatorcontrib>Fung, Chun Yiu Jordan</creatorcontrib><creatorcontrib>Lapadula, Elisa</creatorcontrib><creatorcontrib>Arnoldo, Saranya</creatorcontrib><creatorcontrib>Bearss, Erin</creatorcontrib><creatorcontrib>Binnie, Alexandra</creatorcontrib><creatorcontrib>Borgundvaag, Bjug</creatorcontrib><creatorcontrib>Briollais, Laurent</creatorcontrib><creatorcontrib>Dagher, Marc</creatorcontrib><creatorcontrib>Devine, Luke</creatorcontrib><creatorcontrib>Friedman, Steven M</creatorcontrib><creatorcontrib>Khan, Zeeshan</creatorcontrib><creatorcontrib>Mighton, Chloe</creatorcontrib><creatorcontrib>Nirmalanathan, Konika</creatorcontrib><creatorcontrib>Richardson, David</creatorcontrib><creatorcontrib>Stern, Seth</creatorcontrib><creatorcontrib>Taher, Ahmed</creatorcontrib><creatorcontrib>Wolday, Dawit</creatorcontrib><creatorcontrib>Lerner-Ellis, Jordan</creatorcontrib><creatorcontrib>Taher, Jennifer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Databases</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morgan, Gregory</au><au>Casalino, Selina</au><au>Chowdhary, Sunakshi</au><au>Frangione, Erika</au><au>Fung, Chun Yiu Jordan</au><au>Lapadula, Elisa</au><au>Arnoldo, Saranya</au><au>Bearss, Erin</au><au>Binnie, Alexandra</au><au>Borgundvaag, Bjug</au><au>Briollais, Laurent</au><au>Dagher, Marc</au><au>Devine, Luke</au><au>Friedman, Steven M</au><au>Khan, Zeeshan</au><au>Mighton, Chloe</au><au>Nirmalanathan, Konika</au><au>Richardson, David</au><au>Stern, Seth</au><au>Taher, Ahmed</au><au>Wolday, Dawit</au><au>Lerner-Ellis, Jordan</au><au>Taher, Jennifer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2024-04-19</date><risdate>2024</risdate><volume>42</volume><issue>11</issue><spage>2733</spage><epage>2739</epage><pages>2733-2739</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection.
Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity.
Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1–2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects.
We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>38521677</pmid><doi>10.1016/j.vaccine.2024.03.030</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2024-04, Vol.42 (11), p.2733-2739 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2974008883 |
| source | ScienceDirect Freedom Collection |
| subjects | Adult cohort studies COVID-19 COVID-19 - prevention & control COVID-19 infection COVID-19 vaccines COVID-19 Vaccines - adverse effects Ethnicity Fever Headaches Hospitals Humans Immunization Infections Medical research mRNA mRNA vaccines Observational studies Ontario Ontario - epidemiology Pain Prospective Studies Questionnaires Reactogenicity Regression analysis SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Side effects vaccination Vaccine safety Vaccines |
| title | COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A39%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20vaccine%20reactogenicity%20among%20participants%20enrolled%20in%20the%20GENCOV%20study&rft.jtitle=Vaccine&rft.au=Morgan,%20Gregory&rft.date=2024-04-19&rft.volume=42&rft.issue=11&rft.spage=2733&rft.epage=2739&rft.pages=2733-2739&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2024.03.030&rft_dat=%3Cproquest_cross%3E3037804639%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c374t-a8f92227c9e590e8d2e8f28b1775b2fc694249533e4ab46b636db6f472f005e73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3037804639&rft_id=info:pmid/38521677&rfr_iscdi=true |